Original ArticlePrognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy
Section snippets
Patient selection
This retrospective study included 202 inoperable pulmonary metastases in 118 CRC patients were treated with SBRT from the year 2005 to 2015. Selection criteria for oligometastases included: metastatic disease limited to a maximum of 2 organs and in total no more than 5 metastatic lesions at time of treatment. All oligometastases were treated with either surgery, SBRT, radiofrequency ablation (RFA) or microwave ablation, depending on multidisciplinary tumor board recommendation. The study was
Results
Patient and tumor characteristics are shown in Table 1. The majority of patients (n = 83) had metachronous tumors. One hundred and three patients had more than one metastasis, and extra pulmonary metastases were present in 69 patients. Seventy-three patients received chemotherapy before start of the SBRT.
Median OS was 39.2 months (95% CI 34.8–43.6 months). In total, 55 patients (47%) died and the 2-, 3-, and 5-year OS rates were 69%, 55% and 36%, respectively (Fig. 1a). Median follow-up was
Discussion
In our study, SBRT to pulmonary oligometastases was associated with 2- and 5-year OS rates of 69% and 36%, respectively. SBRT is often offered to patients not fit for other treatment modalities, either due to medical comorbidities, worse general condition or location of metastases. All these parameters can negatively influence OS. Majority of studies evaluating SBRT for pulmonary oligometastases have small sample sizes [14], [15], [16], [17], [18], [19], [20], [21], [22] or include
Conflicts of interest
None.
Acknowledgment
None.
References (43)
- et al.
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab
Clin Colorectal Cancer
(2006) - et al.
Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series
Ann Thorac Surg
(2007) - et al.
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases
J Thorac Cardiovasc Surg
(1997) - et al.
Local tumor control probability modelling of primary and secondary lung tumors in stereotactic body radiotherapy
Radiother Oncol
(2016) - et al.
Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors
Radiother Oncol
(2012) - et al.
Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study
Int J Radiat Oncol Biol Phys
(2015) - et al.
Clinical introduction of Monte Carlo treatment planning: a different prescription dose for non-small cell lung cancer according to tumor location and size
Radiother Oncol
(2010) - et al.
Local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study
Int J Radiat Oncol Biol Phys
(2015) - et al.
Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up
Clin Colo Cancer
(2017) - et al.
Long-term survival after repeated resection of pulmonary metastases from colorectal cancer
Ann Thorac Surg
(2007)
Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
Radiother Oncol
Exploratory analysis on overall survival after either surgery or stereotactic radiotherapy for lung oligometastases from colorectal cancer
Clin Oncol (R Coll Radiol)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic nonsmall-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Lancet Oncol
Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—a pooled analysis of the German working group “stereotactic radiotherapy”
Lung Cancer
Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligometastases
Radiother Oncol
Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival
Ann Oncol
Japanese multiinstitutional study of stereotactic body radiation therapy for totally 380 patients with lung metastases
Int J Radiat Oncol Biol Phys
Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer
Radiother Oncol
Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review
Crit Rev Oncol Hematol
Stereotactic body radiotherapy for oligo-metastatic liver disease – influence of pretreatment chemotherapy and histology on local tumor control
Radiother Oncol
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease
Radiother Oncol
Cited by (23)
Stereotactic Body Radiotherapy for Management of Pulmonary Oligometastases in Stage IV Colorectal Cancer: A Perspective
2023, Clinical Colorectal CancerSafety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme
2021, Clinical Lung CancerCitation Excerpt :Stereotactic body radiotherapy (SBRT) is the standard of care for medically inoperable patients with early-stage non–small-cell lung cancer (NSCLC).1,2 Furthermore, during the past years, it has been established as treatment for pulmonary oligometastases.3-6 Centrally located pulmonary tumors within 2 cm of the proximal bronchial tree (PBT) require cautious treatment owing to reports of excessive toxicity following SBRT with high single doses,2,7 which coined the term “No Fly Zone.”
Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies
2023, Journal of Gastrointestinal Cancer